16 completed, 7 terminated, 7 unknown, 5 recruiting. 40 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 40 | Completed 16, Terminated 7, Unknown 7, Recruiting 5, Active not recruiting 3, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 3, Terminated 2, Active not recruiting 1 |
Follow Mitomycin C: new trials by email Literature Review of Mitomycin C trials Research Report on Mitomycin C
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy - Urothelial Cancer, Urinary Bladder Neoplasms | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 390 | 2026-05-11 | 2026-10-28 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 486 | 2025-10-07 | 2026-10-23 |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer TAR-210, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 220 | 2025-09-10 | 2026-11-03 |
| Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP) Mitomycin c - Pseudomyxoma Peritonei | Phase 3 | Recruiting | University of Southampton | 176 | 2024-12-04 | 2026-02-19 |
| Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery Mitomycin c - Glaucoma | Phase 3 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 144 | 2024-12-01 | 2024-11-08 |
| A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) TAR-200, Mitomycin C, Gemcitabine - Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 272 | 2024-04-09 | 2026-11-03 |
| REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c - Anal Cancer | Phase 2 / Phase 3 | Active not recruiting | University of Cincinnati | 33 | 2023-08-14 | 2025-12-18 |
| Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture Mitomycin c - Urethral Stricture | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2022-01-01 | 2024-01-30 |
| Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Atezolizumab, Biopsy of Bladder, Cisplatin - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 475 | 2019-06-03 | 2026-08-28 |
| The Bladder Instillation Comparison Study Mitomycin C, Gemcitabine - Urinary Bladder Neoplasms | Phase 3 | Completed | Corewell Health West | 101 | 2016-04-19 | 2023-04-21 |
| Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients Paclitaxel, Capecitabine, Mitomycins - Anus Neoplasms, Carcinoma, Squamous Cell | Phase 3 | Unknown | Blokhin's Russian Cancer Research Center | 314 | 2016-01-01 | 2021-02-09 |
| Therapeutic Instillation of Mistletoe abnobaVISCUM 900, Mitomycin C - Superficial Bladder Cancer | Phase 3 | Terminated | Abnoba Gmbh | 174 | 2015-04-01 | 2026-05-22 |
| Mitomicin C for Prevention Postoperative Endoscopic Sinus Surgery Synechia and QOL in Chronic Rhinosinusitis Mitomicin C, Identical placebo solution - Chronic Rhinosinusitis, Postoperative Nasal Synerchia | Phase 3 | Completed | Mahidol University | 224 | 2015-03-01 | 2018-05-23 |
| Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Irradiation, Mitomycin C, 5-Fluorouracil - Anal Carcinoma | Phase 3 | Unknown | University of Erlangen-Nürnberg Medical School | 118 | 2014-12-01 | 2017-08-11 |
| Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer CG0070 Adenovirus Vector, Control Arm: Quadruple Choice - Transitional Cell Carcinoma, Bladder Cancer | Phase 2 / Phase 3 | Terminated | CG Oncology, Inc. | 22 | 2014-03-01 | 2021-04-14 |
| Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma Standard Guarded Trabeculectomy, Mitomycin C, Bevacizumab - Glaucoma | Phase 2 / Phase 3 | Completed | Athens Vision Eye Institute | 40 | 2014-01-01 | 2016-09-15 |
| Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma CyberKnife, TACE, CT Contrast - Carcinoma, Hepatocellular | Phase 3 | Withdrawn | Albert Koong | 2011-02-01 | 2012-06-11 | |
| Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome Bevacizumab, Mitomycin C - Glaucoma | Phase 2 / Phase 3 | Completed | Prince of Songkla University | 39 | 2010-12-01 | 2014-01-31 |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer EN3348, Mitomycin C - Bladder Neoplasm, Neoplasm Recurrence, Local | Phase 3 | Terminated | Bioniche Life Sciences Inc. | 84 | 2010-11-01 | 2017-08-24 |
Showing 20 of 40. Sign in to see all of them.
Urinary Bladder Neoplasms (10) · Anus Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (4) · Glaucoma (4) · Lung Neoplasms (4) · Neoplasms (4) · Non-Muscle Invasive Bladder Neoplasms (4) · Carcinoma, Transitional Cell (3) · Colorectal Neoplasms (3) · Anal Canal Carcinoma (2) · Carcinoma in Situ (2) · Carcinoma, Hepatocellular (2) · Colonic Neoplasms (2) · Neoplasms by Site (2) · Urinary Bladder Diseases (2)
European Organisation for Research and Treatment of Cancer - EORTC (3) · Medical Research Council (3) · National Cancer Institute (NCI) (3) · Janssen Research & Development, LLC (2) · University Hospital Birmingham (2) · Abnoba Gmbh (1) · Ain Shams University (1) · Albert Koong (1) · Alliance for Clinical Trials in Oncology (1) · American College of Radiology Imaging Network (1) · Astellas Pharma Global Development, Inc. (1) · Astex Pharmaceuticals, Inc. (1) · Athens Vision Eye Institute (1) · Bioniche Life Sciences Inc. (1) · Blokhin's Russian Cancer Research Center (1)
United States (17) · United Kingdom (15) · Germany (6) · Belgium (4) · Italy (4) · Netherlands (4) · Canada (3) · Egypt (3) · France (3) · South Korea (3) · Argentina (2) · Brazil (2) · China (2) · Japan (2) · Poland (2)
Ian E. Smith, MD (2) · Adrian Hodson (1) · Al B Benson (1) · Al B. Benson, MD, FACP (1) · Albert Koong (1) · Alex W Yeung, MBBS (1) · Alexander Stojadinovic, MD (1) · Arsen O Rasulov, PhD (1) · Brian R Lane, MD (1) · Faheez Mohamed, MBChB, MD, FRCS (1) · Gerassimos Kopsinis, M.D., Ph.D. (1) · Indy Fernando, MD (1) · Jaffer A. Ajani, MD (1) · James J. Fischer, MD, PhD (1) · Jan B. Vermorken, MD, PhD (1)
PMID 10937547, PMID 16157935, PMID 17122118, PMID 17544497, PMID 18430910, PMID 18486741, PMID 19139424, PMID 19643599, PMID 20564111, PMID 22512481, PMID 23150707, PMID 30274699, PMID 30390114, PMID 31785830, PMID 33539743, PMID 34125951, PMID 36912740, PMID 37012180
2023 (2), P30CA033572 (1), U01CA079778 (1), U01CA080098 (1), U10CA021115 (1), U10CA180820 (1), U10CA180868 (1), U10CA180888 (1)